Learn how doggybone DNA (dbDNA) vaccines offer a safe, scalable alternative to plasmid DNA for cancer immunotherapy, delivering strong immune responses without bacterial components.

Download the full article to learn:

• How dbDNA vaccines can match the immunogenicity of plasmid DNA without bacterial sequences.
• The potential of cell-free, scalable DNA vaccine production for cancer immunotherapy.
• Insights into the use of clinically relevant HPV antigens (E6 and E7) in DNA vaccine development.

This article explores the development of an optimized linear DNA vaccine for influenza using Touchlight’s dbDNA platform. By incorporating neuraminidase (NA) alongside haemagglutinin (HA) and leveraging DNA targeting sequences (DTS), the study demonstrates that dbDNA vaccines can elicit strong immune responses and broaden protection, particularly in cases where HA mutates but NA remains conserved.

Download the full article to learn:

• Insights into how combining HA and NA antigens can enhance the breadth and durability of influenza vaccine protection.
• The role of DNA targeting sequences in boosting immune responses within linear DNA vaccine platforms.
• The advantages of dbDNA technology for rapid, scalable, and cell-free vaccine production.

This article explores how Touchlight’s enzymatically amplified linear dbDNA technology overcomes the limitations of traditional plasmid-based methods in lentiviral vector (LVV) manufacturing. By optimizing vector design and transfection conditions, the study demonstrates that dbDNA can achieve high LVV titres comparable to plasmid-based systems, enabling faster and more scalable GMP-grade production.

What this article covers:

• How dbDNA technology significantly reduces production time and cost compared to plasmid-based methods.
• Understand the specific optimizations that enable high-titre LVV production using linear DNA vectors.
• Gain insights into overcoming bottlenecks in industrial-scale gene therapy manufacturing with innovative vector design

Download the full article below.

This article presents a comparative study between traditional plasmid DNA vaccines and novel enzymatically produced linear DNA constructs known as “Doggybones.” These linear constructs, which exclude unnecessary bacterial elements, demonstrated equivalent gene expression and immune responses in preclinical models, offering a promising alternative for safer and scalable DNA vaccine production.

Download the full article to learn more about:

• How dbDNA  (Doggybone) constructs eliminate unwanted bacterial elements to enhance vaccine safety.
• How these novel constructs perform comparably to plasmids in both gene expression and immune response.
• Explore the potential for large-scale, enzymatic production of DNA vaccines without the need for bacterial culture.

CAR T cell therapy has shown remarkable success in treating blood cancers, but current production methods using viral vectors are extremely expensive, limiting patient access. In this groundbreaking study, researchers explore a promising alternative using dbDNA, an innovative linear DNA vector that could dramatically reduce manufacturing costs while eliminating safety concerns associated with traditional plasmid-based methods.

Download the full article to discover how scientists overcame initial technical challenges to successfully produce functional CAR19 T cells using this novel approach.

CAR T cell therapy has shown remarkable success in treating blood cancers, but current production methods using viral vectors are extremely expensive, limiting patient access. In this groundbreaking study, researchers explore a promising alternative using dbDNA, an innovative linear DNA vector that could dramatically reduce manufacturing costs while eliminating safety concerns associated with traditional plasmid-based methods.

Download the full article to discover how scientists overcame initial technical challenges to successfully produce functional CAR19 T cells using this novel approach.

The most effective way to end the COVID-19 pandemic is through the development of medical countermeasures to combat SARS-CoV-2 infection and disease. The rise of the variants has also illustrated the need for the rapid evolution of vaccines, a niche that is well-suited for nucleic-acid-based vaccines. In this paper, two DNA vaccine approaches are compared: a conventional plasmid DNA vaccine and a novel, synthetic, linear DNA vaccine, comprising doggybone DNA. Both vaccines were protective in a small animal model of severe disease. Moreover, serum from animals vaccinated with SARS-CoV-2 DNA vaccines retained a level of neutralisation against multiple emerging variants.

Download the full article below.

Induced pluripotent stem cells (iPSCs) represent a transformative platform for regenerative medicine and cell therapy, but clinical success depends on safe and reliable reprogramming methods. This study reports the first successful use of Touchlight’s doggybone DNA (dbDNA) vectors to generate human iPSCs, offering a scalable, fully synthetic alternative to traditional plasmid-based episomal systems.

What this article covers:

• Use of dbDNA vectors for efficient iPSC reprogramming without bacterial DNA or p53 shRNA repression
• A direct comparison with OriP/EBNA1 episomal systems, highlighting reduced DNA damage, lower interferon response, and greater genomic stability
• Improvements in cell line stability and reduced spontaneous differentiation
• cGMP-compliant vector production suitable for therapeutic applications

With a reduced immunogenic profile and improved cell health outcomes, dbDNA offers a safer foundation for clinical-grade iPSC generation.

Download the full article to explore how dbDNA vectors advance the safety and stability of cell therapy development.

As advanced therapies continue to transform the healthcare landscape, the need for sustainable manufacturing solutions grows more critical. Traditional plasmid DNA (pDNA) production presents costly, resource-intensive challenges, threatening scalability and accessibility in gene and cell therapies. Touchlight’s innovative dbDNA technology offers an enzymatic alternative that’s efficient, scalable, and environmentally sustainable.

This article explores how dbDNA is reshaping DNA manufacturing and setting new sustainability standards by reducing water use, eliminating bacterial impurities, and minimizing waste. Learn how this pioneering approach unlocks a more sustainable future for genetic medicine.

What You’ll Learn:

• The impact of traditional pDNA production on environmental sustainability
• How dbDNA enables more efficient, scalable, and environmentally friendly manufacturing
• Why sustainable DNA production is vital to advancing gene and cell therapies